Advertisement

Adiponectin and the Cardiovascular System

  • Suketu Shah
  • Alina Gavrila
  • Christos S. Mantzoros
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Adiponectin, a recently discovered protein produced exclusively by adipocytes, is thought to be a possible mediator between obesity, insulin resistance, and cardiovascular disease (CVD). Although its function is not entirely known, body fat distribution, insulin, sex hormones, tumor necrosis factor (TNF)-α, and peroxisome proliferator-activated receptor (PPAR)-α may contribute to its regulation. Along with being associated with cardiovascular risk factors such as diabetes and dyslipidemia, deficiency in adiponectin may also directly compromise endothelial action and promote atherosclerosis.

Keywords

Insulin Resistance Fatty Acid Oxidation Adiponectin Level Plasma Adiponectin Adiponectin Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rajala MW, Scherer PE. Minireview: The adipocytes—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765–3773.PubMedCrossRefGoogle Scholar
  2. 2.
    Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51–59.PubMedCrossRefGoogle Scholar
  3. 3.
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26,746–26,749.PubMedCrossRefGoogle Scholar
  4. 4.
    Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286–289.PubMedCrossRefGoogle Scholar
  5. 5.
    Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10,697–10,703.PubMedCrossRefGoogle Scholar
  6. 6.
    Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996;120:803–812.Google Scholar
  7. 7.
    Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003;88:2838–2843.PubMedCrossRefGoogle Scholar
  9. 9.
    Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459–469.PubMedGoogle Scholar
  10. 10.
    Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003;278:9073–9085.PubMedCrossRefGoogle Scholar
  11. 11.
    Shapiro L, Scherer PE. The crystal structure of a complement-1 q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998;8:335–338.PubMedCrossRefGoogle Scholar
  12. 12.
    Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003;14:447–455.PubMedCrossRefGoogle Scholar
  13. 13.
    Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003;52:1779–1785.PubMedCrossRefGoogle Scholar
  14. 14.
    Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–1599.PubMedGoogle Scholar
  15. 15.
    Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.PubMedCrossRefGoogle Scholar
  16. 16.
    Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594–1602.PubMedCrossRefGoogle Scholar
  17. 17.
    Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799–1804.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim Biophys Acta 2002;1584:115–122.PubMedGoogle Scholar
  19. 19.
    Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with central fat distribution and estrogen levels but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003;88:4823–4831.PubMedCrossRefGoogle Scholar
  20. 20.
    Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730–1736.PubMedCrossRefGoogle Scholar
  21. 21.
    Peake PW, Kriketos AD, Denyer GS, Campbell LV, Charlesworth JA. The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int J Obes Relat Metab Disord 2003;27:657–662.PubMedCrossRefGoogle Scholar
  22. 22.
    English PJ, Coughlin SR, Hayden K, Malik IA, Wilding JP. Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obes Res 2003;11:839–844.PubMedGoogle Scholar
  23. 23.
    Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002;87:5662–5667.PubMedCrossRefGoogle Scholar
  24. 24.
    Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001;288:1102–1107.PubMedCrossRefGoogle Scholar
  25. 25.
    Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;290:1084–1089.PubMedCrossRefGoogle Scholar
  26. 26.
    Mohlig M, Wegewitz U, Osterhoff M, et al. Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002;34:655–658.PubMedCrossRefGoogle Scholar
  27. 27.
    Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734–2741.PubMedCrossRefGoogle Scholar
  28. 28.
    Olefsky JM, Kruszynska YT. Causes of insulin resistance. In: De Groot, L. (ed). De Groot’s Textbook of Endocrinology, 4th ed. WB Saunders: Philadelphia, PA, 2001, pp. 780–782.Google Scholar
  29. 29.
    Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.PubMedCrossRefGoogle Scholar
  30. 30.
    Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002;147:173–180.PubMedCrossRefGoogle Scholar
  31. 31.
    Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre-and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002;367:677–685.PubMedCrossRefGoogle Scholar
  32. 32.
    Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001;507:142–146.PubMedCrossRefGoogle Scholar
  33. 33.
    Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527–E33.PubMedGoogle Scholar
  34. 34.
    Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094–2099.PubMedCrossRefGoogle Scholar
  35. 35.
    Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731–737.PubMedCrossRefGoogle Scholar
  36. 36.
    Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003;92:3J–9J.PubMedCrossRefGoogle Scholar
  37. 37.
    Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376–380.PubMedCrossRefGoogle Scholar
  38. 38.
    Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968–2974.PubMedCrossRefGoogle Scholar
  39. 39.
    Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003;52:1655–1663.PubMedCrossRefGoogle Scholar
  40. 40.
    Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293–300.PubMedCrossRefGoogle Scholar
  41. 41.
    Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325–2328.PubMedCrossRefGoogle Scholar
  42. 42.
    Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25,863–25,866.PubMedCrossRefGoogle Scholar
  43. 43.
    Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126–1133.PubMedCrossRefGoogle Scholar
  44. 44.
    Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–1935.PubMedCrossRefGoogle Scholar
  45. 45.
    Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57–58.PubMedCrossRefGoogle Scholar
  46. 46.
    Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226–228.PubMedCrossRefGoogle Scholar
  47. 47.
    Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003;26:2015–2020.PubMedCrossRefGoogle Scholar
  48. 48.
    Imagawa A, Funahashi T, Nakamura T, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665–1666.PubMedCrossRefGoogle Scholar
  49. 49.
    Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16,309–16,313.PubMedCrossRefGoogle Scholar
  50. 50.
    Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288–1295.PubMedCrossRefGoogle Scholar
  51. 51.
    Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein B J. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003;52:1355–1363.PubMedCrossRefGoogle Scholar
  52. 52.
    Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3–10.PubMedCrossRefGoogle Scholar
  53. 53.
    Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–953.PubMedCrossRefGoogle Scholar
  54. 54.
    Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875–1881.PubMedCrossRefGoogle Scholar
  55. 55.
    Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003;278:45,021–45,026.PubMedCrossRefGoogle Scholar
  56. 56.
    Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.PubMedCrossRefGoogle Scholar
  57. 57.
    Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769.PubMedCrossRefGoogle Scholar
  58. 58.
    Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884–1888.PubMedCrossRefGoogle Scholar
  59. 59.
    Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003;545:103–104.PubMedCrossRefGoogle Scholar
  60. 60.
    Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764–2769.PubMedCrossRefGoogle Scholar
  61. 61.
    Ma K, Cabrero A, Saha PK, et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002;277:34658–34661.PubMedCrossRefGoogle Scholar
  62. 62.
    Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res 2002;10:1016–1020.PubMedCrossRefGoogle Scholar
  63. 63.
    Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231–234.PubMedCrossRefGoogle Scholar
  64. 64.
    Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin in essential hypertension. JNephrol 2002;15:507–511.Google Scholar
  65. 65.
    Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72–75.PubMedCrossRefGoogle Scholar
  66. 66.
    Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002;25:971–976.PubMedCrossRefGoogle Scholar
  67. 67.
    Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab 2003;88:4130–4134.PubMedCrossRefGoogle Scholar
  68. 68.
    Furuhashi M, Ura N, Higashiura K, et al. Blockade of therenin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76–81.PubMedCrossRefGoogle Scholar
  69. 69.
    Miyazaki T, Shimada K, Mokuno H, Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart 2003;89:663.PubMedCrossRefGoogle Scholar
  70. 70.
    Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134–141.PubMedCrossRefGoogle Scholar
  72. 72.
    Kumada M, Kihara S, Sumitsuji S, et al., and the Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85–89.PubMedCrossRefGoogle Scholar
  73. 73.
    Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767–2770.PubMedCrossRefGoogle Scholar
  74. 74.
    Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487–91.PubMedCrossRefGoogle Scholar
  75. 75.
    Krakoff J, Funahashi T, Stehouwer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745–1751.PubMedCrossRefGoogle Scholar
  76. 76.
    Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671–674.PubMedCrossRefGoogle Scholar
  77. 77.
    Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52:942–947.PubMedCrossRefGoogle Scholar
  78. 78.
    Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003;88:2714–2718.PubMedCrossRefGoogle Scholar
  79. 79.
    Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–2476.PubMedGoogle Scholar
  80. 80.
    Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–1301.PubMedGoogle Scholar
  81. 81.
    Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057–1063.PubMedGoogle Scholar
  82. 82.
    Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723–1732.PubMedGoogle Scholar
  83. 83.
    Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893–2898.PubMedCrossRefGoogle Scholar
  84. 84.
    Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003;88:3236–3240.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Suketu Shah
    • 1
  • Alina Gavrila
    • 2
  • Christos S. Mantzoros
    • 2
  1. 1.Division of Endocrinology and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBoston
  2. 2.Division of Endocrinology and Metabolism, Department of Internal MedicineBeth Israel Deaconess Medical CenterBoston

Personalised recommendations